Journal profile · Multiple

Lancet Microbe

ISSN 2666-5247 · Elsevier · United Kingdom

Lancet Microbe: CAS Zone 1 · Biology (2025 upgraded edition, Top journal); impact factor 21.09; fully open access; APC about USD 8,570; median 172 days to acceptance (103 articles, last 24 months); 245 articles in 2025; indexed in SCIE and Scopus.

Impact factor21.09Latest value listed by LetPub
CAS zoneZone 1 · Biology2025 upgraded edition, major category · Top journal · 2026 Xinrui edition Zone 1 · Biology
Review time172 daysMedian, submission to acceptance · 103 articles, last 24 months · PubMed
APCUSD 8,570Fully open access
Acceptance—No reports yet
Articles per year2452025 · OpenAlex count

Scope

Aims, scope and focus

Lancet Microbe is published by Elsevier and is in Zone 1 of Biology in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are SARS-CoV-2 and COVID-19 Research, Antibiotic Resistance in Bacteria and Antibiotic Use and Resistance, together about 23.7% of its articles. Its main subfields are Infectious Diseases. (generated from OpenAlex topic counts and CAS ranking data)

The Lancet Microbe publishes research on clinically relevant microbes at all scales?from the nature of the microbe (eg, antimicrobial resistance genes/plasmids, virulence factors) to the microbiome, to pathology (including immunology) to population level effects (eg, outbreaks, epidemiology). Furthermore, it includes early phase clinical trials and other interventional studies where the outcomes are focused on the pathogen.The Lancet Microbe provides a destination for the best microbiology-focused clinical research. This research is handled in the rigorous manner expected of any journal within the Lancet family. Also in keeping with the Lancet ethos, The Lancet Microbe is a strong advocate for and collaborator with the microbial research community.

From the journal's Aims & Scope

Research area (LetPub): Multiple

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. SARS-CoV-2 and COVID-19 ResearchMedicine9.7%
  2. Antibiotic Resistance in BacteriaBiochemistry, Genetics and Molecular Biology7.8%
  3. Antibiotic Use and ResistanceImmunology and Microbiology6.3%
  4. Tuberculosis Research and EpidemiologyMedicine6%
  5. Viral Infections and Outbreaks ResearchMedicine5.6%
  6. COVID-19 Clinical Research StudiesMedicine5.2%
  7. Respiratory viral infections researchMedicine5.2%
  8. SARS-CoV-2 detection and testingMedicine5.1%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Biology Zone 1
LevelCategoryZone
MajorBiologyZone 1
MinorInfectious DiseasesZone 1
MinorMicrobiologyZone 1

Top journal: yesReview journal: no

CAS Xinrui Journal Ranking (March 2026)Biology Zone 1
LevelCategoryZone
MajorBiologyZone 1
MinorInfectious DiseasesZone 1
MinorMicrobiologyZone 1

Top journal: yesReview journal: not marked

CAS Journal Ranking, previous upgraded edition (December 2023)Biology Zone 1
LevelCategoryZone
MajorBiologyZone 1
MinorInfectious DiseasesZone 1
MinorMicrobiologyZone 1

Top journal: yesReview journal: no

Database indexing

SCIEScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

Impact factor
21.09LetPub ·
Impact factor (publisher)
21.9Publisher website ·
CiteScore 2026-06
24.8LetPub ·
CiteScore (publisher)
24.8Publisher website ·
SJR 2026-06
5.19LetPub ·
SNIP 2026-06
3.83LetPub ·
h-index
93OpenAlex ·
i10-index
664OpenAlex ·
2-year mean citedness
11.98OpenAlex ·
Self-citation rate
1.8%LetPub ·
Share of gold OA articles
99.68%LetPub ·

Volume

Articles per year
118LetPub ·

Articles by year OpenAlex count · 1,490 in total · the current year is incomplete

YearArticlesOpen accessCitations
2026227227268
20252452451,714
20242632636,821
20232222226,773
20222122128,878
20211991998,983

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Review time from article dates manuscript dates registered with PubMed · to

172 daysMedian, submission to acceptance · P25–P75 55 days – 267 days

Acceptance to online
median 74 days (103 articles)
Submission to online
median 288 days
Sample
103 articles with submission and acceptance dates (579 in the window); the latest was accepted on

Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".

Other sources

Average review time (community reports)
about 6 weeksLetPub ·
Submission to first decision
4 daysPublisher website ·
First decision after review
80 daysPublisher website ·
Submission to acceptance
88 daysPublisher website ·
Acceptance to publication
120 daysPublisher website ·
Submission to publication (journal-reported)
about 54 weeksDOAJ ·
Peer review
Single anonymous peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Fully open accessDOAJ

Every article is open access; authors usually pay an article processing charge (APC).

SourceAPCFee waiverLicenseObserved
DOAJUSD 8,570YesCC BY, CC BY-NC, CC BY-NC-ND
OpenAlexUSD 7,280 / EUR 6,810 / GBP 5,830 / JPY 902,940——
LetPubUSD 6,300Yes—
Publisher websiteUSD 8,570——

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Submission

Article types and submission policies (journal website)

Policy excerpts from the journal's websiteOpen access
Open access Open Access

Article Publishing Charge (APC): USD 8,570 (excluding taxes). This journal is taking part in the GPOA program.Review this journal’s open access policy.

Source ↗Publisher website ·

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Profile

Publication details and official links

Publisher
Elsevier
Country or region
United Kingdom
Language
English
ISSN
2666-5247
Official links

FAQ

Frequently asked questions about Lancet Microbe

What CAS zone is Lancet Microbe in?

In the 2025 upgraded edition of the CAS Journal Ranking, Lancet Microbe is in Zone 1 of Biology, and in Zone 1 of the minor category Infectious Diseases / Microbiology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Biology. Zones from different editions, and from major and minor categories, are not interchangeable.

What is the impact factor of Lancet Microbe?

The latest impact factor listed by LetPub is 21.09; CiteScore 24.8, h-index 93.

How long does peer review take at Lancet Microbe?

Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 172 days (interquartile range 55–267 days); authors report an average review time of about 6 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Which databases index Lancet Microbe?

According to LetPub and DOAJ records, Lancet Microbe is indexed in SCIE, Scopus and DOAJ.

Is Lancet Microbe open access, and what is the APC?

Lancet Microbe is a fully open-access journal. APC about USD 8,570.

Sources and updates

The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .